Q-omics provides the consensus-scored REPS1 profile across patient tissues and cancer cell-line models. REPS1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, REPS1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, REPS1 RNA expression shows 20,867 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where REPS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REPS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REPS1 survival associations across molecular data types. REPS1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REPS1 RNA expression–survival associations across cancer types. High REPS1 expression shows unfavorable associations in ACC, BLCA, KIRP, OV and LIHC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for REPS1 RNA expression.
This table summarizes REPS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REPS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REPS1 shows lower tumor expression in THCA and higher tumor expression in COAD, LUSC, HNSC, STAD and BLCA. The COAD box plot shows higher REPS1 RNA expression in tumor versus normal tissue (log2 FC = +0.513, t-test p < 0.001).
This table shows molecular features associated with REPS1 in patient tissues and cancer cell lines. In patient samples, REPS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, REPS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
